Cargando…

Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy

BACKGROUND: Anti-PD-1 therapy has shown significant clinical activity in advanced melanoma. We developed and validated a clinical prediction scale for response to anti- PD-1 monotherapy. METHODS: A total of 315 patients with advanced melanoma treated with pembrolizumab (2 or 10 mg kg(−1) Q2W or Q3W)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nosrati, Adi, Tsai, Katy K, Goldinger, Simone M, Tumeh, Paul, Grimes, Barbara, Loo, Kimberly, Algazi, Alain P, Nguyen-Kim, Thi Dan Linh, Levesque, Mitchell, Dummer, Reinhard, Hamid, Omid, Daud, Adil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418446/ https://www.ncbi.nlm.nih.gov/pubmed/28324889 http://dx.doi.org/10.1038/bjc.2017.70

Ejemplares similares

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
por: Zhao, Bin, et al.
Publicado: (2020)

Predictive models for response and survival in patients treated with anti-PD-1 monotherapy or with anti-PD-1 and ipilimumab combination: editorial commentary
por: Rotte, Anand
Publicado: (2023)

Assessment of the Association between Entropy in PET/CT and Response to Anti-PD-1/PD-L1 Monotherapy in Stage III or IV NSCLC
por: Malet, Julie, et al.
Publicado: (2023)

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
por: Kumar, Utpal, et al.
Publicado: (2021)

Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis
por: Wei, Yuhan, et al.
Publicado: (2020)

Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy
por: Dai, Jie, et al.
Publicado: (2023)

Clinicopathological assessment of PD-1/PD-L1 immune checkpoint expression in desmoid tumors
por: Hashimoto, Kazuhiko, et al.
Publicado: (2023)

Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence
por: Qi, Yihang, et al.
Publicado: (2021)

A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade
por: Milberg, Oleg, et al.
Publicado: (2019)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

PD-1/PD-L1 and DNA Damage Response in Cancer
por: Kciuk, Mateusz, et al.
Publicado: (2023)

Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
por: Glutsch, Valerie, et al.
Publicado: (2019)

High response rate to PD-1 blockade in desmoplastic melanomas
por: Eroglu, Zeynep, et al.
Publicado: (2018)

PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma
por: Bai, Yanhua, et al.
Publicado: (2017)

Integrative assessment of clinicopathological parameters and the expression of PD-L1, PD-L2 and PD-1 in tumor cells of retroperitoneal sarcoma
por: Miyake, Makito, et al.
Publicado: (2020)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

PD-L1 and intratumoral immune response in breast cancer
por: Wang, Zhi-Qiang, et al.
Publicado: (2017)

PD-1 blockade induces responses by inhibiting adaptive immune resistance
por: Tumeh, Paul C., et al.
Publicado: (2014)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
por: Chen, Qi, et al.
Publicado: (2018)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

Identification of the functional PD-L1 interface region responsible for PD-1 binding and initiation of PD-1 signaling
por: Carter, Rachel, et al.
Publicado: (2023)

Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy
por: Ohkuma, Ryotaro, et al.
Publicado: (2023)

Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy
por: Ebot, Ericka M., et al.
Publicado: (2022)

Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases
por: Wang, Haowei, et al.
Publicado: (2023)

Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade
por: Tsai, Katy K., et al.
Publicado: (2016)

Exosomal PD-L1 Contributes to Immunosuppression and is Associated with anti-PD-1 Response
por: Chen, Gang, et al.
Publicado: (2018)

A Systematic Review and Meta-analysis of PD-1 and PD-L1 Inhibitors Monotherapy in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
por: Voutsadakis, Ioannis A
Publicado: (2020)

Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients
por: Starzer, Angelika M, et al.
Publicado: (2021)

A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report
por: Chen, Yi, et al.
Publicado: (2020)

Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study
por: Lang, David, et al.
Publicado: (2019)

Impact of losing adipose tissue on outcomes from PD‐1/PD‐L1 inhibitor monotherapy in non‐small cell lung cancer
por: Nishioka, Naoya, et al.
Publicado: (2022)

Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy
por: García-Aranda, Marilina, et al.
Publicado: (2019)

Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses
por: Bu, Xia, et al.
Publicado: (2021)

Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy
por: Turiello, Roberta, et al.
Publicado: (2020)

In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series
por: Xu, Melody J., et al.
Publicado: (2018)

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
por: Janning, Melanie, et al.
Publicado: (2019)

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series
por: Martini, Dylan J., et al.
Publicado: (2017)

Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer
por: Wang, Yu-meng, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
por: Isla, Dolores, et al.
Publicado: (2023)

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study
por: Elkrief, Arielle, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9gjc0ettbkn60l9hoc7m97cdb4